James Aloysius Brady net worth and biography

James Brady Biography and Net Worth

Director of Xeris Biopharma

James Brady is an experienced international business executive who served in multiple leadership roles of increasing responsibility for AstraZeneca prior to his retirement. His more than thirty years of progressive experience at AstraZeneca included successful national, regional and global finance roles in corporate operations, manufacturing, commercial, marketing, market access, audit, international business, and biologics discovery & development. James most recently served as Chief Financial Officer of MedImmune, the biologics discovery and development division of AstraZeneca. During his tenure at MedImmune, biologics grew to represent more than half of the product development portfolio of AstraZeneca and five biologics were successfully brought to market. Throughout his career at AstraZeneca, James had P&L and management responsibilities for significant operating units and finance functions including MedImmune, the Asia Pacific Region, US Government, Policy and Managed Markets, and Global Marketing. James also served as the Chief Audit Executive for AstraZeneca. His experience spans the full product development cycle from early research and clinical development to sales and product contracting. James currently serves on the Board of Directors and as a Member of the Audit Committee of Verona Pharma plc (Nasdaq: VRNA).

James is a CPA and holds a B.S in Accounting from Saint Joseph University and an MBA from Drexel University.

What is James Aloysius Brady's net worth?: The estimated net worth of James Aloysius Brady is at least $545.70 thousand as of March 30th, 2026. Mr. Brady owns 89,166 shares of Xeris Biopharma stock worth more than $545,696 as of April 16th. This net worth approximation does not reflect any other investments that Mr. Brady may own. Learn More about James Aloysius Brady's net worth.
How do I contact James Aloysius Brady?: The corporate mailing address for Mr. Brady and other Xeris Biopharma executives is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. Xeris Biopharma can also be reached via phone at (844) 445-5704 and via email at [email protected]. Learn More on James Aloysius Brady's contact information.
Has James Aloysius Brady been buying or selling shares of Xeris Biopharma?: James Aloysius Brady has not been actively trading shares of Xeris Biopharma during the last ninety days. Most recently, James Aloysius Brady sold 10,834 shares of the business's stock in a transaction on Monday, March 30th. The shares were sold at an average price of $5.54, for a transaction totalling $60,020.36. Following the completion of the sale, the director now directly owns 89,166 shares of the company's stock, valued at $493,979.64. Learn More on James Aloysius Brady's trading history.
Who are Xeris Biopharma's active insiders?: Xeris Biopharma's insider roster includes Barbara-Jean Bormann-Kennedy (Director), James Brady (Director), Paul Edick (Insider), Dawn Halkuff (Director), Beth Hecht (Insider), John Johnson (Director), Kevin McCulloch (President and Chief Operating Officer), Marla Persky (Director), John Shannon, Jr. (Insider), and Jeffrey Sherman (Director). Learn More on Xeris Biopharma's active insiders.
Are insiders buying or selling shares of Xeris Biopharma?: In the last year, Xeris Biopharma insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $109,500.00. In the last year, insiders at the sold shares 16 times. They sold a total of 532,117 shares worth more than $3,856,303.19. The most recent insider tranaction occured on April, 1st when insider Beth Hecht sold 16,667 shares worth more than $99,835.33. Insiders at Xeris Biopharma own 6.5% of the company. Learn More about insider trades at Xeris Biopharma.
Information on this page was last updated on 4/1/2026.

James Aloysius Brady Insider Trading History at Xeris Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/30/2026	Sell	10,834	$5.54	$60,020.36	89,166

James Aloysius Brady Buying and Selling Activity at Xeris Biopharma

Xeris Biopharma Company Overview

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Today's Range

Now: $6.12

$6.10

$6.27

50 Day Range

MA: $6.10

$5.29

$7.22

2 Week Range

Now: $6.12

$3.95

$10.08

Volume

1,422,533 shs

Average Volume

1,632,936 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77